ClinicalTrials.gg
CompletedNCT03195478Updated Sep 15, 2025Results posted

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

A Phase 1/2 interventional study of Nivolumab and Ipilimumab in Solid Tumor, sponsored by Bristol-Myers Squibb. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mainland Chinese participants with advanced or recurrent solid tumors
  • (ECOG) performance status of 0 or 1
  • One prior anti-cancer therapy that did not work or documented refusal to receive chemotherapy or biological therapy

Exclusion criteria

Exclusion Criteria:

  • Cancer that has spread to the brain or central nervous system unless it has been adequately treated . In addition, either no longer receiving , or on a stable or decreasing dose of no more than 10 mg daily prednisone (or equivalent)
  • Active, known or suspected disease or infection
  • Positive blood screen for chronic infection of or (HCV antibody positive unless HCV RNA is negative)
  • Prior immuno-oncology therapy

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Nivo/Ipi Combination Therapy A

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Nivo/Ipi Combination Therapy B

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Nivo/Ipi Combination Therapy C

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Nivo/Ipi Combination Arm D

    Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • Specified dose on specified days

    Also known as: BMS-734016, Yervoy

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) in Part 1.

    Number of participants with Adverse events

    Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)

  2. Number of Participants With Serious Adverse Events (SAEs) in Part 1.

    Number of participants with Adverse events

    Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)

  3. Number of Participants With Adverse Events Leading to Discontinuation in Part 1.

    Number of participants with Adverse events

    Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)

  4. Number of Participants With Adverse Events Leading to Death in Part 1.

    Number of participants with Adverse Events leading to death.

    Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)

  5. Number of Participants With Clinical Laboratory Abnormalities in Part 1.

    Number of participants with clinical laboratory abnormalities.

    Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)

  6. BICR-Assessed ORR in Part 2

    ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by BICR, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).

    Time frame: between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first as assessed by BICR. (Approximately on average 3.21 Months)

Secondary outcomes

  1. Cmax - Maximum Observed Serum Concentration in Part 1.

    Cmax - Maximum observed serum concentration in Part 1.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  2. Tmax - Time of Maximum Observed Serum Concentration in Part 1.

    Tmax - Time of maximum observed serum concentration in Part 1.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  3. AUC(0-T) - Area Under the Plasma Concentration-time Curve in Part 1.

    AUC(0-T) - Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration. in Part 1.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  4. AUC(TAU) - Area Under the Concentration-time Curve in One Dosing Interval in Part 1.

    AUC(TAU) - Area under the concentration-time curve in one dosing interval in Part 1.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  5. Ceoinf - Serum Concentration Achieved at the End of Study Drug Infusion in Part 1.

    Ceoinf - Serum concentration achieved at the end of study drug infusion in Part 1.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  6. Ctau - Concentration at the End of Dosing Interval in Part 1.

    Ctau - Concentration at the end of dosing interval in Part 1. The Ctau is equivilant to the CTrough at these time points.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  7. CLT - Total Body Clearance in Part 1.

    CLT - Total body clearance in Part 1.

    Time frame: At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  8. Css-avg - Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) in Part 1.

    Css-avg - Average concentration over a dosing interval (AUC(TAU)/tau) in Part 1.

    Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  9. AI - Accumulation Index in Part 1.

    AI - Accumulation index; ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC (TAU) in Part 1. Here SS = Steady State Here FD = First Dose

    Time frame: At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  10. T-HALFeff - Effective Elimination Half-life in Part 1.

    T-HALFeff - Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC(TAU), Cmax, or Ctau) in Part 1.

    Time frame: At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)

  11. Number of Participants With Nivolumab Anti Drug Antibodies in Part 1.

    Number of participants with nivolumab Anti Drug Antibodies in Part 1.

    Time frame: At baseline and from first dose to last dose (Approximately on average of Arm A 24.54 weeks, Arm B 76 weeks, Arm C 92.5 Weeks)

  12. Number of Participants With Ipilimumab Anti Drug Antibodies in Part 1.

    Number of participants with Ipilimumab Anti Drug Antibodies in Part 1.

    Time frame: At baseline and from first dose to last dose (Approximately on average of Arm A 24.54 weeks, Arm B 76 weeks, Arm C 92.5 Weeks)

  13. Investigator-Assessed ORR in Part 2

    ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by Investigator, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).

    Time frame: between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first as assessed by the Investigator. (Approximately on average 2 Months)

  14. Investigator-Assessed Disease Control Rate (DCR) in Part 2

    The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per investigator.

    Time frame: between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 as assessed by the Investigator. (Approximately on average 5 Months)

  15. BICR-Assessed Disease Control Rate (DCR) in Part 2

    The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per BICR.

    Time frame: Approximately 5.92 Months

  16. BICR-Assessed Duration of Response (DOR) in Part 2

    The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.

    Time frame: From first dose to 100 days post last dose (approximately 102 weeks)

  17. Investigator-Assessed Duration of Response (DOR) in Part 2

    The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.

    Time frame: From first dose to 100 days post last dose (approximately 102 weeks)

  18. BICR-Assessed Progression Free Survival (PFS) in Part 2

    The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.

    Time frame: From first dose to 100 days post last dose (approximately 102 weeks)

  19. Investigator-Assessed Progression Free Survival (PFS) in Part 2

    The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.

    Time frame: From first dose to 100 days post last dose (approximately 102 weeks)

07

Results

Posted Sep 15, 2025
Limitations and caveats
"AUC(TAU) for ipi in Arm A, Cycle 1 and Cycle 3 could not be reported because there were not enough PK samples collected. Samples were only taken up to 336 hours after dosing, but the full TAU is 1008 hours, so it was not possible to calculate AUC(TAU) for these cycles. In Cycle 2, only a single PK sample was collected (at Week 3, prior to nivo dose administration) for both nivo and ipi. Therefore, AUC(TAU) could not be calculated or reported for nivo and ipi in Arm A, Cycle 2."

Participant flow

Participant flow — Overall Study
MilestonePart 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm D
Started9999
Completed1417
Not completed8582
Withdrew: Disease progression5461
Withdrew: Study drug toxicity2001
Withdrew: Participant requested to discontinue study treatment0100
Withdrew: Participant withdrew consent1000
Withdrew: Maximum clinical benefit0010
Withdrew: Other reasons0010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) in Part 1.

Number of participants with Adverse events

Time frame:
From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Number of Participants With Adverse Events (AEs) in Part 1.799
PrimaryNumber of Participants With Serious Adverse Events (SAEs) in Part 1.

Number of participants with Adverse events

Time frame:
From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Number of Participants With Serious Adverse Events (SAEs) in Part 1.433
PrimaryNumber of Participants With Adverse Events Leading to Discontinuation in Part 1.

Number of participants with Adverse events

Time frame:
From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Number of Participants With Adverse Events Leading to Discontinuation in Part 1.300
PrimaryNumber of Participants With Adverse Events Leading to Death in Part 1.

Number of participants with Adverse Events leading to death.

Time frame:
From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Death in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Number of Participants With Adverse Events Leading to Death in Part 1.110
PrimaryNumber of Participants With Clinical Laboratory Abnormalities in Part 1.

Number of participants with clinical laboratory abnormalities.

Time frame:
From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Any Grade597
Grade 3-4141
PrimaryBICR-Assessed ORR in Part 2

ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by BICR, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).

Time frame:
between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first as assessed by BICR. (Approximately on average 3.21 Months)
Reported as:
Number · Percentage of Participants
BICR-Assessed ORR in Part 2
Percentage of ParticipantsPart 2: Arm D
BICR-Assessed ORR in Part 277.8 (40.0 to 97.2)
SecondaryCmax - Maximum Observed Serum Concentration in Part 1.

Cmax - Maximum observed serum concentration in Part 1.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · ug/mL
Cmax - Maximum Observed Serum Concentration in Part 1.
ug/mLPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 159.7 ± 1969.5 ± 1922.5 ± 14
Nivo Cycle 2—104 ± 1227.2 ± 21
Nivo Cycle 3122 ± 21——
Ipi Cycle 118.9 ± 1816.8 ± 4355.0 ± 33
Ipi Cycle 2—22.0 ± 1664.1 ± 29
Ipi Cycle 320.1 ± 17——
SecondaryTmax - Time of Maximum Observed Serum Concentration in Part 1.

Tmax - Time of maximum observed serum concentration in Part 1.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Median · Hours
Tmax - Time of Maximum Observed Serum Concentration in Part 1.
HoursPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 11.68 (1.6 to 8.0)1.62 (1.5 to 48.0)1.59 (1.5 to 1.6)
Nivo Cycle 2—1.55 (1.5 to 47.9)4.78 (1.6 to 8.0)
Nivo Cycle 31.65 (1.6 to 8.0)——
Ipi Cycle 10.617 (0.5 to 7.0)6.83 (0.5 to 46.9)0.517 (0.5 to 6.8)
Ipi Cycle 2—6.98 (0.5 to 7.0)0.542 (0.5 to 6.9)
Ipi Cycle 36.78 (0.5 to 6.9)——
SecondaryAUC(0-T) - Area Under the Plasma Concentration-time Curve in Part 1.

AUC(0-T) - Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration. in Part 1.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · h*ug/mL
AUC(0-T) - Area Under the Plasma Concentration-time Curve in Part 1.
h*ug/mLPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 110329 ± 2114141 ± 264056 ± 25
Nivo Cycle 2—23348 ± 284323 ± 39
Nivo Cycle 323147 ± 31——
Ipi Cycle 12847 ± 183377 ± 279893 ± 21
Ipi Cycle 2—4959 ± 2811388 ± 34
Ipi Cycle 33480 ± 18——
SecondaryAUC(TAU) - Area Under the Concentration-time Curve in One Dosing Interval in Part 1.

AUC(TAU) - Area under the concentration-time curve in one dosing interval in Part 1.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · h*ug/mL
AUC(TAU) - Area Under the Concentration-time Curve in One Dosing Interval in Part 1.
h*ug/mLPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 110333 ± 2113919 ± 264002 ± 19
Nivo Cycle 2—24467 ± 234647 ± 48
Nivo Cycle 328098 ± 18——
Ipi Cycle 1—3339 ± 279808 ± 17
Ipi Cycle 2—5377 ± 2012206 ± 36
SecondaryCeoinf - Serum Concentration Achieved at the End of Study Drug Infusion in Part 1.

Ceoinf - Serum concentration achieved at the end of study drug infusion in Part 1.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · ug/mL
Ceoinf - Serum Concentration Achieved at the End of Study Drug Infusion in Part 1.
ug/mLPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 159.4 ± 1968.4 ± 2122.5 ± 14
Nivo Cycle 2—99.5 ± 1525.4 ± 24
Nivo Cycle 3120 ± 21——
Ipi Cycle 117.7 ± 2614.0 ± 5054.8 ± 33
Ipi Cycle 2—16.3 ± 3962.7 ± 27
Ipi Cycle 317.1 ± 33——
SecondaryCtau - Concentration at the End of Dosing Interval in Part 1.

Ctau - Concentration at the end of dosing interval in Part 1. The Ctau is equivilant to the CTrough at these time points.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · ug/mL
Ctau - Concentration at the End of Dosing Interval in Part 1.
ug/mLPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 119.7 ± 2416.0 ± 323.46 ± 32
Nivo Cycle 2—40.6 ± 303.32 ± 70
Nivo Cycle 363.2 ± 24——
Ipi Cycle 14.85 ± 253.22 ± 348.72 ± 33
Ipi Cycle 2—6.74 ± 2415.4 ± 27
Ipi Cycle 36.07 ± 20——
SecondaryCLT - Total Body Clearance in Part 1.

CLT - Total body clearance in Part 1.

Time frame:
At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · mL/h
CLT - Total Body Clearance in Part 1.
mL/hPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 2—8.56 ± 3713.1 ± 51
Nivo Cycle 36.99 ± 16——
Ipi Cycle 2—13.0 ± 3615.0 ± 55
Ipi Cycle 3NA ± NA——
SecondaryCss-avg - Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) in Part 1.

Css-avg - Average concentration over a dosing interval (AUC(TAU)/tau) in Part 1.

Time frame:
At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · ug/mL
Css-avg - Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) in Part 1.
ug/mLPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 130.8 ± 2127.6 ± 267.94 ± 19
Nivo Cycle 2—48.5 ± 239.22 ± 48
Nivo Cycle 383.6 ± 18——
Ipi Cycle 1—6.63 ± 2719.5 ± 17
Ipi Cycle 2—10.7 ± 2024.2 ± 36
SecondaryAI - Accumulation Index in Part 1.

AI - Accumulation index; ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC (TAU) in Part 1. Here SS = Steady State Here FD = First Dose

Time frame:
At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · ratio of AUC(Tau) at SS vs FD
AI - Accumulation Index in Part 1.
ratio of AUC(Tau) at SS vs FDPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 2—1.65 ± 221.13 ± 30
Nivo Cycle 32.71 ± 4——
Ipi Cycle 2—1.50 ± 201.26 ± 22
Ipi Cycle 3NA ± NA——
SecondaryT-HALFeff - Effective Elimination Half-life in Part 1.

T-HALFeff - Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC(TAU), Cmax, or Ctau) in Part 1.

Time frame:
At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Reported as:
Geometric mean · Hours
T-HALFeff - Effective Elimination Half-life in Part 1.
HoursPart 1: Arm APart 1: Arm BPart 1: Arm C
Nivo Cycle 2—385 ± 36263 ± 37
Nivo Cycle 3507 ± 4——
Ipi Cycle 2—325 ± 38282 ± 14
Ipi Cycle 3NA ± NA——
SecondaryNumber of Participants With Nivolumab Anti Drug Antibodies in Part 1.

Number of participants with nivolumab Anti Drug Antibodies in Part 1.

Time frame:
At baseline and from first dose to last dose (Approximately on average of Arm A 24.54 weeks, Arm B 76 weeks, Arm C 92.5 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Nivolumab Anti Drug Antibodies in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Baseline ADA Positive020
ADA Positive003
Neutralizing Positive001
ADA Negative994
SecondaryNumber of Participants With Ipilimumab Anti Drug Antibodies in Part 1.

Number of participants with Ipilimumab Anti Drug Antibodies in Part 1.

Time frame:
At baseline and from first dose to last dose (Approximately on average of Arm A 24.54 weeks, Arm B 76 weeks, Arm C 92.5 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Ipilimumab Anti Drug Antibodies in Part 1.
ParticipantsPart 1: Arm APart 1: Arm BPart 1: Arm C
Baseline ADA Positive102
ADA Positive000
Neutralizing Positive000
ADA Negative997
SecondaryInvestigator-Assessed ORR in Part 2

ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by Investigator, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).

Time frame:
between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first as assessed by the Investigator. (Approximately on average 2 Months)
Reported as:
Number · Percentage of Participants
Investigator-Assessed ORR in Part 2
Percentage of ParticipantsPart 2: Arm D
Investigator-Assessed ORR in Part 266.7 (29.9 to 92.5)
SecondaryInvestigator-Assessed Disease Control Rate (DCR) in Part 2

The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per investigator.

Time frame:
between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 as assessed by the Investigator. (Approximately on average 5 Months)
Reported as:
Number · Percentage of Participants
Investigator-Assessed Disease Control Rate (DCR) in Part 2
Percentage of ParticipantsPart 2: Arm D
Investigator-Assessed Disease Control Rate (DCR) in Part 288.9 (51.8 to 99.7)
SecondaryBICR-Assessed Disease Control Rate (DCR) in Part 2

The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per BICR.

Time frame:
Approximately 5.92 Months
Reported as:
Number · Percentage of Participants
BICR-Assessed Disease Control Rate (DCR) in Part 2
Percentage of ParticipantsPart 2: Arm D
BICR-Assessed Disease Control Rate (DCR) in Part 288.9 (51.8 to 99.7)
SecondaryBICR-Assessed Duration of Response (DOR) in Part 2

The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.

Time frame:
From first dose to 100 days post last dose (approximately 102 weeks)
Reported as:
Median · Months
BICR-Assessed Duration of Response (DOR) in Part 2
MonthsPart 2: Arm D
BICR-Assessed Duration of Response (DOR) in Part 2NA (15.21 to NA)
SecondaryInvestigator-Assessed Duration of Response (DOR) in Part 2

The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.

Time frame:
From first dose to 100 days post last dose (approximately 102 weeks)
Reported as:
Median · Months
Investigator-Assessed Duration of Response (DOR) in Part 2
MonthsPart 2: Arm D
Investigator-Assessed Duration of Response (DOR) in Part 2NA (NA to NA)
SecondaryBICR-Assessed Progression Free Survival (PFS) in Part 2

The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.

Time frame:
From first dose to 100 days post last dose (approximately 102 weeks)
Reported as:
Median · Months
BICR-Assessed Progression Free Survival (PFS) in Part 2
MonthsPart 2: Arm D
BICR-Assessed Progression Free Survival (PFS) in Part 2NA (1.22 to NA)
SecondaryInvestigator-Assessed Progression Free Survival (PFS) in Part 2

The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.

Time frame:
From first dose to 100 days post last dose (approximately 102 weeks)
Reported as:
Median · Months
Investigator-Assessed Progression Free Survival (PFS) in Part 2
MonthsPart 2: Arm D
Investigator-Assessed Progression Free Survival (PFS) in Part 2NA (1.22 to NA)

Adverse events

Collected over All-Cause mortality, Adverse Events and Serious Adverse Events: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months and Arm D: 23.8 Months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Arm A2/9 (22.2%)4/9 (44.4%)7/9 (77.8%)
Part 1: Arm B2/9 (22.2%)3/9 (33.3%)9/9 (100%)
Part 1: Arm C1/9 (11.1%)3/9 (33.3%)9/9 (100%)
Part 2: Arm D1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPart 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm D
AnaemiaBlood and lymphatic system disorders1/90/90/90/9
Thyroiditis subacuteEndocrine disorders0/91/90/90/9
PancreatitisGastrointestinal disorders0/90/90/91/9
VomitingGastrointestinal disorders0/90/91/90/9
Hepatic function abnormalHepatobiliary disorders0/91/90/91/9
Liver injuryHepatobiliary disorders0/90/91/90/9
CellulitisInfections and infestations0/91/90/90/9
PneumoniaInfections and infestations0/90/91/90/9
Alanine aminotransferase increasedInvestigations0/90/90/91/9
MalnutritionMetabolism and nutrition disorders0/90/90/91/9
Most frequent other events
Showing 10 of 144
Most frequent other events
EventPart 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm D
AnaemiaBlood and lymphatic system disorders4/96/92/93/9
PyrexiaGeneral disorders5/92/96/92/9
Aspartate aminotransferase increasedInvestigations1/93/94/96/9
HypothyroidismEndocrine disorders1/93/93/95/9
Alanine aminotransferase increasedInvestigations1/93/94/95/9
PruritusSkin and subcutaneous tissue disorders1/93/95/92/9
LeukopeniaBlood and lymphatic system disorders1/94/90/90/9
HyperthyroidismEndocrine disorders0/91/94/91/9
Blood bilirubin increasedInvestigations0/92/92/94/9
Blood creatine phosphokinase increasedInvestigations0/93/94/91/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm DTotal
<=18 years00000
Between 18 and 65 years788629
>=65 years21137
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm DTotal
Female134513
Male865423
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm DTotal
Hispanic or Latino00000
Not Hispanic or Latino00000
Unknown or Not Reported999936
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Arm APart 1: Arm BPart 1: Arm CPart 2: Arm DTotal
American Indian or Alaska Native00000
Asian999936
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

12 sites
  • Local Institution - 0015
    Beijing, Beijing Municipality 100021, China
  • Local Institution - 0001
    Beijing, Beijing Municipality 100142, China
  • Local Institution
    Guangzhou, Guangdong 510080, China
  • Local Institution - 0012
    Guangzhou, Guangdong 510655, China
  • Local Institution - 0011
    Harbin, Heilongjiang 155040, China
  • Local Institution
    Zhengzhou, Henan 450052, China
  • Local Institution - 0021
    Wuhan, Hubei 430030, China
  • Local Institution - 0020
    Xi'an, Shan1xi 710061, China
  • Local Institution - 0016
    Shanghai, Shanghai Municipality 200025, China
  • Local Institution - 0018
    Chengdu, Sichuan 610041, China
  • Local Institution - 0004
    Tianjin, Tianjin Municipality 300222, China
  • Local Institution - 0013
    Hangzhou, Zhejiang 310009, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jan 2024, 77 months.

Results were first posted in Sep 2025, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jun 22, 2017
StartActual
Aug 2, 2017
Primary completionActual
Jan 5, 2024
CompletionActual
Jan 5, 2024
Results first posted
Sep 15, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03195478
Responsible party
Sponsor
First posted
Jun 22, 2017
Start date
Aug 2, 2017
Primary completion
Jan 5, 2024
Completion
Jan 5, 2024
Results posted
Sep 15, 2025
Last update
Sep 15, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion